{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:13:04Z","timestamp":1761513184251,"version":"build-2065373602"},"reference-count":29,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2006,2,1]],"date-time":"2006-02-01T00:00:00Z","timestamp":1138752000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2006,2,1]],"date-time":"2006-02-01T00:00:00Z","timestamp":1138752000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinical-breast-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Breast Cancer"],"published-print":{"date-parts":[[2006,2]]},"DOI":"10.3816\/cbc.2006.n.004","type":"journal-article","created":{"date-parts":[[2008,9,10]],"date-time":"2008-09-10T21:07:37Z","timestamp":1221080857000},"page":"511-517","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Phase II Study of Neoadjuvant Docetaxel\/Vinorelbine Followed by Surgery and Adjuvant Doxorubicin\/Cyclophosphamide in Women with Stage II\/III Breast Cancer"],"prefix":"10.3816","volume":"6","author":[{"given":"Steven A.","family":"Limentani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam M.","family":"Brufsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John K.","family":"Erban","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammed","family":"Jahanzeb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deborah","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.3816\/CBC.2006.n.004_bib1","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S0889-8588(05)70065-4","article-title":"Locally advanced breast cancer","volume":"13","author":"Esteva","year":"1999","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.3816\/CBC.2006.n.004_bib2","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1200\/JCO.1999.17.2.460","article-title":"Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy","volume":"17","author":"Kuerer","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2006.n.004_bib3","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1200\/JCO.1998.16.8.2672","article-title":"Effect of preoperative chemotherapy on the outcome of women with operable breast cancer","volume":"6","author":"Fisher","year":"1998","journal-title":"J Clin Oncol"},{"issue":"suppl 9","key":"10.3816\/CBC.2006.n.004_bib4","first-page":"1","article-title":"Single agent docetaxel (Taxotere) in randomized phase III trials","volume":"26","author":"Burris","year":"1999","journal-title":"Semin Oncol"},{"issue":"suppl 8","key":"10.3816\/CBC.2006.n.004_bib5","first-page":"21","article-title":"Phase I-II studies of docetaxel as a single agent in the treatment of metastatic breast cancer","volume":"26","author":"Trudeau","year":"1999","journal-title":"Semin Oncol"},{"key":"10.3816\/CBC.2006.n.004_bib6","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1200\/JCO.1999.17.8.2341","article-title":"Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer","volume":"17","author":"Chan","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2006.n.004_bib7","first-page":"36","article-title":"Neoadjuvant docetaxel followed by adjuvant doxorubicin and cyclophosphamide for stage III breast cancer: clinical response and long-term survival","volume":"22","author":"Swain","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.3816\/CBC.2006.n.004_bib8","doi-asserted-by":"crossref","first-page":"3033","DOI":"10.1200\/JCO.1999.17.10.3033","article-title":"Combination versus sequential doxorubicin and docetaxel as primary chemotherapy for breast cancer: a randomized pilot trial of the Hoosier Oncology Group","volume":"17","author":"Miller","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2006.n.004_bib9","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1200\/JCO.1999.17.7.1999","article-title":"Maximized reduction of primary breast tumor size using preoperative chemotherapy with doxorubicin and docetaxel","volume":"17","author":"von Minckwitz","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2006.n.004_bib10","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1093\/annonc\/mdg449","article-title":"Phase II trial combining docetaxel and doxorubicin as neoadjuvant chemotherapy in patients with operable breast cancer","volume":"14","author":"Ganem","year":"2003","journal-title":"Ann Oncol"},{"key":"10.3816\/CBC.2006.n.004_bib11","first-page":"S50","article-title":"Primary endpoint analysis of the Geparduo-Study-preoperative chemotherapy (PCT) comparing dose-dense versus sequential adriamycin\/docetaxel combination in operable breast cancer (T2-3, N0-2, M0)","volume":"70","author":"Jackisch","year":"2002","journal-title":"Breast Cancer Res Treat"},{"key":"10.3816\/CBC.2006.n.004_bib12","first-page":"32a","article-title":"A phase II neoadjuvant trial of sequential doxorubicin and docetaxel for the treatment of stage III breast cancer measuring signal transducers and activators of transcription (STAT) activation as a predictor of response to therapy","volume":"21","author":"Minton","year":"2002","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.3816\/CBC.2006.n.004_bib13","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0305-7372(96)90032-8","article-title":"Vinorelbine: an overview","volume":"22","author":"Johnson","year":"1996","journal-title":"Cancer Treat Rev"},{"key":"10.3816\/CBC.2006.n.004_bib14","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1200\/JCO.1995.13.12.2879","article-title":"Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer","volume":"13","author":"Ravdin","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2006.n.004_bib15","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1200\/JCO.1994.12.10.2094","article-title":"Vinorelbine is an active antiproliferative agent in pretreated advanced breast cancer patients: a phase II study","volume":"12","author":"Gasparini","year":"1994","journal-title":"J Clin Oncol"},{"issue":"suppl 4","key":"10.3816\/CBC.2006.n.004_bib16","first-page":"3","article-title":"Preclinical evaluation of docetaxel (Taxotere)","volume":"22","author":"Lavelle","year":"1995","journal-title":"Semin Oncol"},{"issue":"suppl 7","key":"10.3816\/CBC.2006.n.004_bib17","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1016\/S0959-8049(97)90005-8","article-title":"Docetaxel in combination with doxorubicin or vinorelbine","volume":"33","author":"Dieras","year":"1997","journal-title":"Eur J Cancer"},{"key":"10.3816\/CBC.2006.n.004_bib18","first-page":"119a","article-title":"A phase II study of docetaxel (D) and vinorelbine (V) in metastatic breast cancer (MBC)","volume":"18","author":"De Paz","year":"1999","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.3816\/CBC.2006.n.004_bib19","first-page":"87","article-title":"Docetaxel and vinorelbine in patients with metastatic breast cancer after using anthracyclines","volume":"57","author":"G\u00f3mez-Bernal","year":"1999","journal-title":"Breast Cancer Res Treat"},{"key":"10.3816\/CBC.2006.n.004_bib20","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1097\/01.COC.0000017091.69111.94","article-title":"Biweekly docetaxel and vinorelbine in anthracycline-resistant metastatic breast cancer: a multicenter phase II study","volume":"26","author":"G\u00f3mez-Bernal","year":"2003","journal-title":"Am J Clin Oncol"},{"key":"10.3816\/CBC.2006.n.004_bib21","first-page":"88","article-title":"Docetaxel + vinorelbine with concurrent G-CSF support: a phase II study in stage IV breast cancer","volume":"57","author":"Gralow","year":"1999","journal-title":"Breast Cancer Res Treat"},{"key":"10.3816\/CBC.2006.n.004_bib22","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1023\/A:1020273502426","article-title":"Docetaxel plus vinorelbine as salvage chemotherapy in advanced breast cancer: a phase II study","volume":"76","author":"Rodriguez","year":"2002","journal-title":"Breast Cancer Res Treat"},{"key":"10.3816\/CBC.2006.n.004_bib23","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1200\/JCO.2000.18.6.1346","article-title":"Phase II trial of docetaxel and vinorelbine in patients with advanced non-small-cell lung cancer","volume":"18","author":"Miller","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2006.n.004_bib24","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1200\/JCO.2003.09.081","volume":"21","author":"Citron","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2006.n.004_bib25","doi-asserted-by":"crossref","first-page":"4165","DOI":"10.1200\/JCO.2003.12.005","article-title":"The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project protocol B-27","volume":"21","author":"Bear","year":"2003","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"10.3816\/CBC.2006.n.004_bib26","first-page":"S16","article-title":"A randomized trial comparing preoperative (preop) doxorubicin\/cyclophosphamide (AC) to preop AC followed by preop docetaxel (T) and to preop AC followed by postoperative (postop) T in patients with operable carcinoma of the breast: results of NSABP B-27","volume":"88","author":"Bear","year":"2004","journal-title":"Breast Cancer Res Treat"},{"key":"10.3816\/CBC.2006.n.004_bib27","first-page":"43a","article-title":"Dose-dense versus sequential adriamycin\/docetaxel combination as preoperative chemotherapy (pCHT) in operable breast cancer (T2-3, N0-2, M0) - primary endpoint analysis of the Geparduo-study","volume":"21","author":"von Minckwitz","year":"2002","journal-title":"Proc Am Soc Clin Oncol"},{"issue":"14 suppl","key":"10.3816\/CBC.2006.n.004_bib28","first-page":"82s","article-title":"TAC as neoadjuvant chemotherapy in patients with primary breast cancer - interim progress report on 907 cases of the randomized prospective Gepartrio-trial","volume":"22","author":"Costa","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2006.n.004_bib29","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1385\/MO:20:3:221","article-title":"The role of biological markers as predictors of response to preoperative chemotherapy in large primary breast cancer","volume":"20","author":"Cocquyt","year":"2003","journal-title":"Med Oncol"}],"container-title":["Clinical Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820911704712?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820911704712?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:08:50Z","timestamp":1761512930000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1526820911704712"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,2]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2006,2]]}},"alternative-id":["S1526820911704712"],"URL":"https:\/\/doi.org\/10.3816\/cbc.2006.n.004","relation":{},"ISSN":["1526-8209"],"issn-type":[{"type":"print","value":"1526-8209"}],"subject":[],"published":{"date-parts":[[2006,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase II Study of Neoadjuvant Docetaxel\/Vinorelbine Followed by Surgery and Adjuvant Doxorubicin\/Cyclophosphamide in Women with Stage II\/III Breast Cancer","name":"articletitle","label":"Article Title"},{"value":"Clinical Breast Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.3816\/CBC.2006.n.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2006 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}